Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

An interdisciplinary research team from Leipzig University and the Saxon AI center ScaDS.AI has developed a novel approach ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Roseman University of Health Sciences in Henderson announced today it has been designated a research institution by the Carnegie Classification. Roseman is the third ...

Intelligent Omics' Dr Rob Grundy discusses how combining AI with big data can lead to better drug discovery processes and that partnerships can help more organisations leverage cutting-edge tools.

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and ...

Neuropsychiatric disorders are becoming increasingly prevalent. Given their complex and multifactorial pathogenesis, there is ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...